

# Neurotrophic Keratitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/N8CB5DF29737EN.html>

Date: May 2024

Pages: 136

Price: US\$ 6,499.00 (Single User License)

ID: N8CB5DF29737EN

## Abstracts

The 7 major neurotrophic keratitis markets reached a value of US\$ 137.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 248.0 Million by 2034, exhibiting a growth rate (CAGR) of 5.51% during 2024-2034.

The neurotrophic keratitis market has been comprehensively analyzed in IMARC's new report titled "Neurotrophic Keratitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neurotrophic keratitis is a degenerative corneal condition caused by sensory innervation impairment in the cornea. Based on the severity of the disease, it can be classified into stages I, II, and III. Neurotrophic keratitis is characterized by reduced or absent corneal sensation, resulting in spontaneous epithelial breakdown, poor corneal recovery, and, eventually, the development of corneal ulceration, melting, and perforation. The symptoms of this ailment can vary but typically involve redness, stinging, burning, or irritation of the eyes, along with mucus discharge and decreased or blurred vision. The other rare symptoms associated with this condition include sensitivity to light and discomfort wearing contact lenses. The diagnosis of the ailment generally involves a comprehensive eye examination, such as a visual acuity test and a detailed evaluation of the cornea. Various specialized tests, including corneal sensitivity testing and confocal microscopy, are used to confirm the diagnosis and assess the severity of the disease. In some cases, numerous imaging studies, such as computed tomography (CT) or magnetic resonance imaging (MRI), may be necessary to rule out other underlying conditions.

The rising incidences of trigeminal nerve damage caused by several associated risk factors, such as infectious disorders like herpes simplex virus (HSV), eye or facial region trauma, systemic diseases, including diabetes mellitus and multiple sclerosis,

etc., are primarily augmenting the neurotrophic keratitis market. In addition to this, the widespread adoption of nerve growth factor (NGF) eye drops as a novel treatment option since it improves corneal sensitivity, lowers corneal ulceration, and enhances vision in patients is further creating a positive outlook for the market. Moreover, the increasing utilization of amniotic membrane transplantation, which utilizes growth factors and anti-inflammatory cytokines that promote corneal healing and reduce scarring, for treating neurotrophic keratitis, is also acting as a significant growth-inducing factor. Additionally, the inflating application of non-pharmacological treatments for neurotrophic keratitis, such as therapeutic scleral and corneal contact lenses, to stimulate epithelial healing of the cornea and decrease corneal complications is further propelling the market growth. Besides this, the introduction of new formulations of corticosteroids for treating the disease, including loteprednol etabonate, which reduces the risk of side effects like elevated intraocular pressure, is expected to drive the neurotrophic keratitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the neurotrophic keratitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neurotrophic keratitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neurotrophic keratitis market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the neurotrophic keratitis market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the neurotrophic keratitis market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current neurotrophic keratitis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

## Market Insights

How has the neurotrophic keratitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the neurotrophic keratitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the neurotrophic keratitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of neurotrophic keratitis across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of neurotrophic keratitis by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of neurotrophic keratitis by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with neurotrophic keratitis across the seven major markets?

What is the size of the neurotrophic keratitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of neurotrophic keratitis?

What will be the growth rate of patients across the seven major markets?

## Neurotrophic Keratitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for neurotrophic keratitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neurotrophic keratitis market?

What are the key regulatory events related to the neurotrophic keratitis market?

What is the structure of clinical trial landscape by status related to the neurotrophic keratitis market?

What is the structure of clinical trial landscape by phase related to the neurotrophic keratitis market?

What is the structure of clinical trial landscape by route of administration related to the neurotrophic keratitis market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 NEUROTROPHIC KERATITIS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
- 4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
- 4.5 Competitive Intelligence

### **5 NEUROTROPHIC KERATITIS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 NEUROTROPHIC KERATITIS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (?2018-2023?)
  - 7.2.2 Epidemiology Forecast (?2024-2034?)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (?2018-2023?)
  - 7.3.2 Epidemiology Forecast (?2024-2034?)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.5 Epidemiology by Gender (?2018-2034?)
  - 7.3.6 Diagnosed Cases (?2018-2034?)
  - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (?2018-2023?)
  - 7.4.2 Epidemiology Forecast (?2024-2034?)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (?2018-2023?)
  - 7.5.2 Epidemiology Forecast (?2024-2034?)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (?2018-2023?)
  - 7.6.2 Epidemiology Forecast (?2024-2034?)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (?2018-2023?)
  - 7.7.2 Epidemiology Forecast (?2024-2034?)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (?2018-2023?)
  - 7.8.2 Epidemiology Forecast (?2024-2034?)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (?2018-2023?)
  - 7.9.2 Epidemiology Forecast (?2024-2034?)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 NEUROTROPHIC KERATITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 NEUROTROPHIC KERATITIS - UNMET NEEDS**

## **10 NEUROTROPHIC KERATITIS - KEY ENDPOINTS OF TREATMENT**

## **11 NEUROTROPHIC KERATITIS - MARKETED PRODUCTS**

- 11.1 List of Neurotrophic Keratitis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Oxervate (Cenegermin) - Dompe Farmaceutici
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.



## **12 NEUROTROPHIC KERATITIS - PIPELINE DRUGS**

### 12.1 List of Neurotrophic Keratitis Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Udonitrectag - Recordati Rare Diseases

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. NEUROTROPHIC KERATITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. NEUROTROPHIC KERATITIS – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 NEUROTROPHIC KERATITIS - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Neurotrophic Keratitis - Market Size

##### 15.2.1.1 Market Size (?2018-2023?)

##### 15.2.1.2 Market Forecast (?2024-2034?)

#### 15.2.2 Neurotrophic Keratitis - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (?2018-2023?)

##### 15.2.2.2 Market Forecast by Therapies (?2024-2034?)

### 15.3 Market Scenario - United States

#### 15.3.1 Neurotrophic Keratitis - Market Size

##### 15.3.1.1 Market Size (?2018-2023?)

##### 15.3.1.2 Market Forecast (?2024-2034?)

#### 15.3.2 Neurotrophic Keratitis - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (?2018-2023?)

- 15.3.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.3.3 Neurotrophic Keratitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Neurotrophic Keratitis - Market Size
    - 15.4.1.1 Market Size (?2018-2023?)
    - 15.4.1.2 Market Forecast (?2024-2034?)
  - 15.4.2 Neurotrophic Keratitis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (?2018-2023?)
    - 15.4.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.4.3 Neurotrophic Keratitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Neurotrophic Keratitis - Market Size
    - 15.5.1.1 Market Size (?2018-2023?)
    - 15.5.1.2 Market Forecast (?2024-2034?)
  - 15.5.2 Neurotrophic Keratitis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (?2018-2023?)
    - 15.5.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.5.3 Neurotrophic Keratitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Neurotrophic Keratitis - Market Size
    - 15.6.1.1 Market Size (?2018-2023?)
    - 15.6.1.2 Market Forecast (?2024-2034?)
  - 15.6.2 Neurotrophic Keratitis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (?2018-2023?)
    - 15.6.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.6.3 Neurotrophic Keratitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Neurotrophic Keratitis - Market Size
    - 15.7.1.1 Market Size (?2018-2023?)
    - 15.7.1.2 Market Forecast (?2024-2034?)
  - 15.7.2 Neurotrophic Keratitis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (?2018-2023?)
    - 15.7.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.7.3 Neurotrophic Keratitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Neurotrophic Keratitis - Market Size
    - 15.8.1.1 Market Size (?2018-2023?)
    - 15.8.1.2 Market Forecast (?2024-2034?)
  - 15.8.2 Neurotrophic Keratitis - Market Size by Therapies

15.8.2.1 Market Size by Therapies (?2018-2023?)

15.8.2.2 Market Forecast by Therapies (?2024-2034?)

15.8.3 Neurotrophic Keratitis - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Neurotrophic Keratitis - Market Size

15.9.1.1 Market Size (?2018-2023?)

15.9.1.2 Market Forecast (?2024-2034?)

15.9.2 Neurotrophic Keratitis - Market Size by Therapies

15.9.2.1 Market Size by Therapies (?2018-2023?)

15.9.2.2 Market Forecast by Therapies (?2024-2034?)

15.9.3 Neurotrophic Keratitis - Access and Reimbursement Overview

## **16 NEUROTROPHIC KERATITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 NEUROTROPHIC KERATITIS MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 NEUROTROPHIC KERATITIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Neurotrophic Keratitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/N8CB5DF29737EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N8CB5DF29737EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

